immunomodulatory treatment by rituximab
Phase 3Monoclonal antibody
immunomodulatory treatment by rituximab is one of 10 small molecule programs targeting Psychiatric Disorder. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Psychiatric Disorder
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Lexapro
AbbVieApproved
Chantix
PPrism Pharmaceuticals
Approved
Pitocin
RRetrophin
Approved
Suboxone
IIndivior Inc.
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
immunomodulatory treatment by rituximab
UUniversity Hospital, Bordeaux
Phase 3
Dayvigo
EisaiPreclinical
Skyclarys
BiogenPreclinical
Conservative Treatment
PPeking University Third Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity Hospital, Bordeaux